Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 19INDUSTRY 10OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Esophageal Squamous Cell Carcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Chemotherapy 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Pemetrexed 6Cisplatin 6Nivolumab 5Gemcitabine 5Drug Therapy 5Radiotherapy 4Docetaxel 4pembrolizumab 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Endostatins 3Carboplatin 3tislelizumab 2endostar protein 2durvalumab 2camrelizumab 2Thalidomide 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Gefitinib 2Erlotinib Hydrochloride 2Bevacizumab 2Afatinib 2trilaciclib 1toripalimab 1titanium silicide 1osimertinib 1olaparib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Non-Small-Cell Lung × toripalimab × Clear all
NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Fujian Cancer Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡